Cargando…

Risk assessment and molecular mechanism study of drug-drug interactions between rivaroxaban and tyrosine kinase inhibitors mediated by CYP2J2/3A4 and BCRP/P-gp

Cancer patients generally has a high risk of thrombotic diseases. However, anticoagulant therapy always aggravates bleeding risks. Rivaroxaban is one of the most widely used direct oral anticoagulants, which is used as anticoagulant treatment or prophylaxis in clinical practice. The present study ai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Tingting, Li, Xuening, Chen, Yanwei, Du, Jie, Chen, Xiaodong, Wang, Dalong, Wang, Liyan, Zhao, Shan, Wang, Changyuan, Meng, Qiang, Sun, Huijun, Liu, Kexin, Wu, Jingjing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441481/ https://www.ncbi.nlm.nih.gov/pubmed/36071847 http://dx.doi.org/10.3389/fphar.2022.914842

Ejemplares similares

Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P‐gp and BCRP
por: Ou, Ying C., et al.
Publicado: (2021)

Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors
por: Lemos, C, et al.
Publicado: (2008)

Recent advances in the search of BCRP- and dual P-gp/BCRP-based multidrug resistance modulators
por: Dei, Silvia, et al.
Publicado: (2019)

Inflammation Induces Changes in the Functional Expression of P-gp, BCRP, and MRP2: An Overview of Different Models and Consequences for Drug Disposition
por: Saib, Sonia, et al.
Publicado: (2021)

ABC transporters P-gp and Bcrp do not limit the brain uptake of the novel antipsychotic and anticonvulsant drug cannabidiol in mice
por: Brzozowska, Natalia, et al.
Publicado: (2016)

Integrated safety analysis of rolapitant with coadministered drugs from phase II/III trials: an assessment of CYP2D6 or BCRP inhibition by rolapitant
por: Barbour, S., et al.
Publicado: (2017)

Cannabidiol changes P-gp and BCRP expression in trophoblast cell lines
por: Feinshtein, Valeria, et al.
Publicado: (2013)

Allicin affects the pharmacokinetics of sulfadiazine and florfenicol by downregulating the expression of jejunum P-gp and BCRP in broilers
por: Wang, Xiaoming, et al.
Publicado: (2022)

Effect of enzalutamide on PK of P‐gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters
por: Poondru, Srinivasu, et al.
Publicado: (2022)

Dual Inhibition of P-gp and BCRP Improves Oral Topotecan Bioavailability in Rodents
por: Lee, Jaeok, et al.
Publicado: (2021)

Virtual Screening of DrugBank Reveals Two Drugs as New BCRP Inhibitors
por: Montanari, Floriane, et al.
Publicado: (2016)

Evaluation of Drug–Drug Interactions of Rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P‐gp Substrates in Patients With an Advanced Solid Tumor
por: Xiao, Jim J., et al.
Publicado: (2018)

Organic anion transporters also mediate the drug–drug interaction between imipenem and cilastatin
por: Zhu, Yanna, et al.
Publicado: (2020)

Cellular Models and In Vitro Assays for the Screening of modulators of P-gp, MRP1 and BCRP
por: Gameiro, Mariline, et al.
Publicado: (2017)

Changes in Expression and Function of Placental and Intestinal P-gp and BCRP Transporters during Pregnancy
por: Szatmári, Péter, et al.
Publicado: (2023)

Characterization of three naturally occurring lignans, sesamol, sesamolin, and sesamin, as potent inhibitors of human cytochrome P450 46A1: Implications for treating excitatory neurotoxicity
por: Du, Jie, et al.
Publicado: (2022)

Modulating Drug Resistance by Targeting BCRP/ABCG2 Using Retrovirus-Mediated RNA Interference
por: Xie, Ni, et al.
Publicado: (2014)

Adenine: an important drug scaffold for the design of antiviral agents
por: Wang, Changyuan, et al.
Publicado: (2015)

Impact of the Genotype and Phenotype of CYP3A and P-gp on the Apixaban and Rivaroxaban Exposure in a Real-World Setting
por: Lenoir, Camille, et al.
Publicado: (2022)

Chicken xenobiotic receptor upregulates the BCRP/ABCG2 transporter
por: Xu, Ziyong, et al.
Publicado: (2022)

Correction: Modulating Drug Resistance by Targeting BCRP/ABCG2 Using Retrovirus-Mediated RNA Interference
Publicado: (2014)

Effects of vercirnon on the activity of CYP3A4, CYP2C19 and CYP2C8 enzymes and BCRP and OATP1B1 transporters using probe substrates
por: Haberer, Lynda J., et al.
Publicado: (2013)

Physiologically‐based pharmacokinetic modeling of quinidine to establish a CYP3A4, P‐gp, and CYP2D6 drug–drug–gene interaction network
por: Feick, Denise, et al.
Publicado: (2023)

Physiologically-based pharmacokinetic predictions of intestinal BCRP-mediated drug interactions of rosuvastatin in Koreans
por: Bae, Soo Hyeon, et al.
Publicado: (2018)

BCRP/ABCG2 in the Placenta: Expression, Function and Regulation
por: Mao, Qingcheng
Publicado: (2008)

BCRP/ABCG2 in the Placenta: Expression, Function and Regulation
por: Mao, Qingcheng
Publicado: (2008)

The PI3K subunits, P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer
por: Zhang, Lei, et al.
Publicado: (2020)

Insights into CYP2B6-mediated drug–drug interactions
por: Hedrich, William D., et al.
Publicado: (2016)

BCRP/ABCG2 Inhibition Sensitizes Hepatocellular Carcinoma Cells to Sorafenib
por: Huang, Wei-Chien, et al.
Publicado: (2013)

Selectivity profiling of BCRP versus P-gp inhibition: from automated collection of polypharmacology data to multi-label learning
por: Montanari, Floriane, et al.
Publicado: (2016)

In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor
por: Zhang, Heather, et al.
Publicado: (2021)

Expression of ABCG2 (BCRP) in mouse models with enhanced erythropoiesis
por: Latunde-Dada, Gladys O., et al.
Publicado: (2014)

The Effect of Albumin on MRP2 and BCRP in the Vesicular Transport Assay
por: Deng, Feng, et al.
Publicado: (2016)

Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates
por: Otsuka, Yukio, et al.
Publicado: (2023)

Adjudin disrupts spermatogenesis by targeting drug transporters: Lesson from the breast cancer resistance protein (BCRP)
por: Qian, Xiaojing, et al.
Publicado: (2013)

Cannabis constituents interact at the drug efflux pump BCRP to markedly increase plasma cannabidiolic acid concentrations
por: Anderson, Lyndsey L., et al.
Publicado: (2021)

Evaluation of the CYP3A and CYP2B6 Drug‐Drug Interaction Potential of Lemborexant
por: Landry, Ishani, et al.
Publicado: (2021)

Application of physiologically‐based pharmacokinetic model approach to predict pharmacokinetics and drug–drug interaction of rivaroxaban: A case study of rivaroxaban and carbamazepine
por: Ngo, Lien Thi, et al.
Publicado: (2022)

Hypoxia‐inducible factor‐2α directly promotes BCRP expression and mediates the resistance of ovarian cancer stem cells to adriamycin
por: He, Miao, et al.
Publicado: (2019)

Development of precision medicine approaches based on inter-individual variability of BCRP/ABCG2
por: Chen, Liming, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3jlnpjfcks72rgvn6cn5021eel